ImmunoGen, Inc.
Nov 13, 2015

ImmunoGen Named One of The Boston Globe's Top Places to Work for Third Consecutive Year

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received this recognition for the third consecutive year and in four of the last five years.

"We are extremely pleased that ImmunoGen has once again been recognized as one of The Boston Globe's Top Places to Work," commented Daniel Junius, President and CEO. "It is the expertise and dedication of our entire organization that has brought ImmunoGen to where we are today: a company with a validated technology, a highly promising lead product program moving into a study we intend to use for registration purposes, a rich pipeline and partnerships with a number of leading healthcare companies. We are proud that we continue to attract and retain employees who are committed to our mission of making a difference in the lives of patients with cancer."

The Boston Globe's 2015 Top Places to Work recognizes the most admired workplaces in the state. The rankings in Top Places to Work are based on confidential survey information collected by WorkplaceDynamics, an independent company specializing in employee engagement and retention, from nearly 77,000 individuals at a wide array of Massachusetts organizations. The survey measures employee opinions about their company's direction, execution, connection, management, work, pay and benefits, and engagement. The winners share a few key traits, including offering progressive benefits, giving their employees a voice, and encouraging them to have some fun while they're at it.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for FRα-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including mirvetuximab soravtansine (IMGN853), including risks related to clinical studies and regulatory processes, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2015 and other reports filed with the Securities and Exchange Commission.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600

Source: ImmunoGen, Inc.

News Provided by Acquire Media